NRX Pharmaceuticals, Inc. - FORM 10-Q - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - November 16, 2020

Attached files

file filename
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - NRX Pharmaceuticals, Inc.brpa_322.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - NRX Pharmaceuticals, Inc.brpa_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - NRX Pharmaceuticals, Inc.brpa_ex311.htm
10-Q - QUARTERLY REPORT - NRX Pharmaceuticals, Inc.brpa_10q.htm
 
 
 
EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. 1350
(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)
 
In connection with the accompanying Quarterly Report on Form 10-Q of Big Rock Partners Acquisition Corp. (the “Company”) for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge and belief, that:
 
1. 
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2. 
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: November 16, 2020
By:
/s/ Richard Ackerman
 
 
Richard Ackerman
 
 
Chairman, President and Chief Executive Officer
 
 
(Principal Executive Officer)
  
 

NRX Pharmaceuticals, Inc. Reports